Cytel, Sumitomo deal

Sumitomo exercised its option to license CYTL's CY-1748 P-selectin antibody, which has

Read the full 123 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE